|
KMID : 1040120160020020059
|
|
Evidence and Values in Healthcare
2016 Volume.2 No. 2 p.59 ~ p.69
|
|
|
Comparison of effects of atypical long-acting injections and oral agents in schizophrenia for 6 months follow-up: a prospective multicenter registry study
|
|
Park Chan-Mi
Lee Seung-Hwan
Bae Kyung-Yeol
Choi Mi-Young
Kim Young-Hoon
Chung Young-Chul
Lee Sang-Kyu
Won Seung-Hee
Ko Min-Jung
Tak Ji-Yeun
Park Eun-Jung
Tchoi Ha-Jin
Park Seon-Cheol
Choi Jin-A
Suh Jae-Kyung
Kim Ji-Young
|
|
|
Abstract
|
|
|
Objectives: To compare the clinical outcomes between the schizophrenia patients using long-acting injection (LAI)
and those using oral agent (Oral).
Methods: A prospective multicenter registry conducted at 7 hospitals comparing a one-year treatment effectiveness
of LAI to reduce recurrence and to improve medication adherence (MA) and quality of life (QOL). This interim
analysis presents data from the first 6 months of the follow-up period.
Results: Among a total of 393 patients enrolled in this study, 385 patients (LAI 87, Oral 298) were analyzed as the
interim analysis. There were no significant differences in clinical global impression (CGI), global improvement (GI),
positive and negative symptom scale (PANSS), and QOL (CGI, P=0.618; GI, P=0.599; PANSS, P=0.289; EuroQol five
dimensions questionnaire, P=0.254; Korean version of 4th revision of Schizophrenia Quality of Life Scale, P=0.416;
visual analogue scale, P=0.581). LAI was associated with improved doctor’s perspective MA (P=0.021), but no difference
was observed in patient’s perspective MA (P=0.355). Recurrence for 6 months occurred in 8 cases (9.2%) of
LAI and in 43 cases (14.4%) of Oral. Kaplan-Meier analysis showed that there was no significant difference in time
to recurrence after enrollment between LAI and Oral. The multivariate Cox analysis also showed no difference (hazard
ratio=1.710; 95% confidence interval=0.758~3.855).
Conclusion: In patients with schizophrenia experiencing recurrence, the difference of effectiveness between LAI and
oral therapy could not be observed during 6 months of follow-up.
|
|
|
KEYWORD
|
|
|
Schizophrenia, Antipsychotics, Prospective studies, Multicenter study
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|